Navigation Links
PegIFN-lambda shows superior virological response and improved safety than PegIFN-alpha-2a
Date:4/2/2011

Berlin, Germany, 02 April 2011: Highly exciting new data presented today at the International Liver CongressTM found Pegylated Interferon-lambda (PegIFN-lambda) shows superior virological response in HCV patients of genotypes 1-4, with improved safety and tolerability, compared to Pegylated Interferon-alpha (PegIFN-alpha-2a), the current standard of care in chronic HCV.1

The study results are so important because they show PegIFN-lambda could provide relief for the 20% of HCV patients who have to undergo dose reduction, or cease treatment, on PegIFN-alpha-2a a part of the current HCV standard of care.2

The trial shows that PegIFN-lambda provides higher rapid virological response (RVR) and complete early virological response (cEVR) than PegIFN-alpha-2a, even in patients with an unfavourable IL28B genotype which predisposes patients to be resistant to treatment.

Both RVR and cEVR are important markers of a drug's ability to combat HCV infection: RVR is measured as undetectable HCV RNA at week 4 of therapy, maintained up to end of treatment; cEVR is detectable HCV RNA at week 4, but undetectable at week 12, maintained up to end of treatment.

Results at week 12 of the trial show that those HCV genotype 1 and 4 patients given 180g of PegIFN-lambda achieved RVR 14.7% of the time and cEVR 55.9% of time, compared to 5.8% RVR and 37.9% cEVR in patients given the same dose of PegIFN-alpha-2a.

The study also found PegIFN-lambda was associated with fewer hematologic (blood cell) toxicities, flu-like symptoms, musculoskeletal symptoms, dose reductions and premature discontinuations than the same dose of PegIFN-alpha-2a. However, in the higher dose groups elevations of ALT and bilirubin were observed which may represent drug related toxicity.

Professor Heiner Wedemeyer, EASL's Secretary General, commented: "These are clearly very early results but the combination of better virological response and fewer side effects mak
'/>"/>

Contact: Travis Taylor
easlpressoffice@cohnwolfe.com
44-784-306-9451
European Association for the Study of the Liver
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. First blinded study of venous insufficiency prevalence in MS shows promising results
2. People with anxiety disorder less able to regulate response to negative emotions, study shows
3. Poll Shows Eroding Support for Health Reform
4. Protecting patients: Study shows that Johns Hopkins flu vaccination rates twice national average
5. Compound shows promise against intractable heart failure
6. Drama or reality TV: Do medical shows depict proper first aid for seizures?
7. TV Shows Often Botch Proper Seizure Responses
8. UQ research shows canecutters disease on the rise among travelers
9. Brain Scan Shows What Beauty is Worth
10. Untreated poor vision in elderly linked to dementia, University of Michigan study shows
11. New research shows emotional impact of low sexual desire and associated distress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Spring is the perfect time to ... filled with whole foods to weather perfect for outdoor ... season the nutrition experts at Brilliant Nutrition highlight five ... , 1. Eating Locally, With the abundance of fresh ... and explore, spring is a great time to take ...
(Date:5/21/2013)... Feed additives have now become an ... chain. Most of the feed additives are used in ... and powders. There are variety of feed additives available ... upon the type of animal and feed. Nutritional feed ... essential nutrition to the animal in order to gain ...
(Date:5/21/2013)... Daily Gossip Magazine published well-documented articles that are ... people informed on the latest weight loss methods by publishing ... in-depth review of Kyle Leon’s Customized Fat ... want to lose weight or stay in shape with the ... was created by a popular fitness trainer, Kyle Leon, who ...
(Date:5/21/2013)... DISCcert has served the training industry for ... DISC applications at the July 25 & 26th ... July 25 & 26th DISC certification in San Diego, ... DISC. The time-tested, proven support materials will include valuable ... training materials ; worksheets, handouts, learning activities, power-points ...
(Date:5/21/2013)... 2013) Prostaglandin analogues (PGAs), drugs which lower intraocular ... people with glaucoma, but their use is not without ... dryness, changes in eye color and other side effects. ... also cause upper and lower eyelid drooping and other ... described in PLOS ONE . , Researchers from ...
Breaking Medicine News(10 mins):Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 2Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 3Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 2Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 3Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 4Health News:Customized Fat Loss Plan Review and Diet Secrets Revealed By Daily Gossip Magazine 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4Health News:Glaucoma drug can cause droopy eyelids 2
... Inc. (Nasdaq: MSON ), a developer of ... is used for the ablation of tumors and worldwide ... has purchased three patents associated with High Intensity Focused ... relate to HIFU transducer arrays method of fabrication, ultrasonic ...
... with rheumatic diseases want more information and better communication ... their conditions, according to the results of a new ... of the European League Against Rheumatism in Copenhagen, Denmark. ... understand the importance of addressing sexual health with their ...
... Friday 12 June 2009: After five years of receiving ... spondylitis (AS) showed substantial clinical benefit (ASAS40, ASsessment in ... at five years, 78.4% of AS patients had no ... junction between tendon and bone). Over this period, patients ...
... CHICAGO, June 12 Germany ... by the eastern federal states.,This is in large part ... despite the economic crisis. American investor interest in,Germany remains ... Nordex AG shared their success stories at the "How,Far ...
... , Travelers Turn to InsureMyTrip.com for Coverage Protection and ... Stating ,the scientific criteria for an influenza pandemic have ... declared the A(H1N1) virus, commonly referred to as Swine ... http://www.newscom.com/cgi-bin/prnh/20070529/NETU076LOGO ) , , "Particularly ...
... 12 June 2009: 92.8% of patients with systemic lupus ... both their physical and emotional quality of life (QoL), ... today at EULAR 2009, the Annual Congress of the ... analysis revealed that depression was the most significant factor ...
Cached Medicine News:Health News:Misonix Announces the Purchase of Patents From ProRhythm, Inc. 2Health News:Misonix Announces the Purchase of Patents From ProRhythm, Inc. 3Health News:Better access to info and dialogue with HCPs on sexual issues for rheumatology patients 2Health News:Better access to info and dialogue with HCPs on sexual issues for rheumatology patients 3Health News:IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS 2Health News:IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS 3Health News:American Investors Highlight Successes in Eastern Germany 2Health News:World Health Organization Declares A(H1N1) Pandemic 2Health News:World Health Organization Declares A(H1N1) Pandemic 3Health News:Anxiety and depression lower quality of life in majority of systemic lupus erythematosus patients 2
(Date:5/21/2013)... 21, 2013  BioRestorative Therapies, Inc. ("BRT" or the ... on developing stem cell based therapies for various personal ... its President and CEO, will be presenting at the ... be held on Thursday, May 30, 2013 at the ... in New York City.  Mr. Weinreb,s presentation will take ...
(Date:5/21/2013)... , May 21, 2013 Ceregene, ... secondary analysis of its double-blind, randomized, controlled Phase ... a gene therapy product designed to deliver the ... analysis identified a more robust response to CERE-120 ... to treatment relative to those diagnosed 10 years ...
(Date:5/21/2013)... MONROVIA, Calif. , May 21, 2013 ... leading developer, manufacturer and marketer of minimally invasive ophthalmic ... upcoming investor conferences to review the Company,s recent financial ... STAAR Surgical will present at the 38 ... Boston at the Westin Waterfront ...
Breaking Medicine Technology:BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5STAAR Surgical To Present At Upcoming Investor Conferences 2
... COLLEGEVILLE, Pa., and TARRYTOWN, N.Y., May 22 ... ), and Progenics,Pharmaceuticals, Inc. (Nasdaq: PGNX ), ... with investigational oral and,intravenous formulations of RELISTOR(TM) (methylnaltrexone ... phase 2 trial, evaluated the effects of,an oral ...
... LAS VEGAS, May 22 CardioVascular,BioTherapeutics, Inc. (OTC Bulletin ... Christopher Moore to be the sponsor and general,partner of ... of,$1 million and up to $10 million of the ... am extremely impressed with CVBT,s wound healing drug, which ...
Cached Medicine Technology:Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 2Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 3Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 4Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 5Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 6Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 7Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 2Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 3
... Adjustable Post-Operative Pin Knee Brace (POP) for ... associated with ACL, PCL, MCL, and LCL ... extension in 7 increments. Can be locked ... increases compliance. Breakaway hinge bar converts long ...
... The Aircast Patellar Brace is a ... unique "horseshoe" shaped aircell stabilizes the patella ... maintain the position of the patella. During ... helping to reduce swelling and pain. A ...
... Pediatric Knee/Elbow Cryo/Cuff is specifically designed to treat ... the therapeutic benefits of controlled compression to minimize ... Due to the unique design of the cuff, ... knee and elbow of the patient. The Pediatric ...
... therapeutic benefits of controlled compression to minimize hemarthrosis ... cuff is anatomically designed to completely fit the ... available in three sizes for adults and is ... children 1 - 7 years of age. A ...
Medicine Products: